Please login to the form below

Not currently logged in
Email:
Password:

Morphotek

This page shows the latest Morphotek news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

Mesothelin is expressed at elevated levels by a number of cancer types, including prostate and bile duct cancer, and  has also been targeted by antibody-based drugs such as Morphotek’s

Latest news

  • Christina Coughlin to leave Immunocore for Tmunity Christina Coughlin to leave Immunocore for Tmunity

    She went on to lead early development programmes at Novartis, including in checkpoint and PI3K inhibitors, and then leadership roles at Morphotek, Pfizer and Wyeth.

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials.

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other types of cancer.". ... Eisai acquired Morphotek in 2007 in a $325m deal designed to bring in a portfolio of oncology drug candidates.

  • Eisai subsidiary in tie up for prostate cancer antibodies

    Eisai subsidiary Morphotek signs a R&D agreement with the National Cancer Institute for the development of therapeutic antibodies to a cancer-associated protein. ... Morphotek will apply its proprietary Morphodoma antibody technology to the development

  • Eisai acquires MGI Pharma for USD 3.9bn

    In 2006, Eisai bought four cancer drugs from Ligand Pharmaceuticals for a total of USD 205m, while in early 2007 the company spent USD 325m on the buy up of Morphotek.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    68. Sorrento Therapeutics / Morphotek. Research and option agreement. To generate chemotherapeutic antibody drug conjugates (ADCs) (platform).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics